BioSpace News Archive

Able Medical Devices today announced the launch of Valkyrie® Looped Sternotomy Sutures.

CardioRenal Systems, Inc. announced today that the FDA granted Breakthrough Device Designation for its RenalGuard Therapy® device for the prevention of Acute Kidney Injury (AKI) in patients at risk for Cardiac Surgery Associated AKI (CSA-AKI).

Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced the appointment of three new members to the executive leadership team who will oversee and execute key aspects of commercialization and clinical research for its flagship solution, CardioFlux.

For more detail related to the fiscal year 2023 unaudited second quarter results, please visit our web site.

This Strategic Partnership will enable EMMA International and Thema to Increase Their Geographical Offerings for the Medical Device Industry

ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE).

On the journey from gene to protein, a nascent RNA molecule can be cut and joined, or spliced, in different ways before being translated into a protein.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2022 financial results on Thursday, February 2, 2023, before the market opens.

Kerecis, the company pioneering the use of fish skin and fatty acids for tissue regeneration and protection, announced the release of two new products for the burn market, GraftGuide Mano™ and GraftGuide Micro™.

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS) announced today that it has amended certain financial terms of the $20 million convertible note issued by its partner, Cytovia Therapeutics, LLC (“Cytovia”) in payment of the upfront collaboration consideration provided for pursuant to the research collaboration and non-exclusive license agreement between Cellectis and Cytovia.